by Peter Ciszewski | May 3, 2021
Howard Trachtman, MD, from NYU Langone Health, provides an overview of the safety and efficacy of sparsentan to treat focal segmental glomerulosclerosis (FSGS). FSGS is a heterogeneous kidney disorder that often presents with a variable degree of proteinuria...
by Peter Ciszewski | Apr 30, 2021
Jonathan Troost, PhD, from the Michigan Institute for Clinical and Health Research at the University of Michigan, discusses the statistical analysis that determined if proteinuria is a viable outcome measure for focal segmental glomerulosclerosis (FSGS). FSGS...
by Peter Ciszewski | Apr 30, 2021
Michael Hayden, MBChB, PhD, CEO of Prilenia Therapeutics and a Killam Professor at the University of British Columbia, discusses the PROOF-HD trial. The PROOF-HD trial is testing the safety and efficacy of pridopidine in patients with early stage Huntington...
by Peter Ciszewski | Apr 29, 2021
Florence Wong, MD, Professor of Medicine at the University of Toronto, gives an overview of hepatorenal syndrome type 1 (HRS-1). As Dr. Wong explains, HRS-1 is a life-threatening syndrome involving acute kidney failure in patients with cirrhosis and ascites. It...
by Peter Ciszewski | Apr 27, 2021
Howard Trachtman, MD, Pediatric Nephrologist at NYU Langone Health provides an overview of focal segmental glomerulosclerosis (FSGS). FSGS is a heterogeneous kidney disorder best defined as glomerular histopathology. Patients with FSGS typically present with a...
